Guidelines for incorporating scientific knowledge and practice on rare diseases into higher education: Neuronal ceroid lipofuscinoses as a model disorder

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 10, 2015, Pages 2316-2323

  Cismondi, Inés Adriana ^a,b   Kohan, Romina ^a,b   Adams, Heather ^d   Bond, Mike ^e   Brown, Rachel ^e   Cooper, Jonathan D ^f   de Hidalgo, Perla K ^b   Holthaus, Sophia Martha Kleine ^e,h   Mole, Sara E ^e   Mugnaini, Julia ^a   de Ramirez, Ana María Oller ^a   Pesaola, Favio ^a,c   Rautenberg, Gisela ^a   Platt, Frances M ^g   de Halac, Inés Noher ^a,c  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Advocacy; Education; Neuronal ceroid lipofuscinoses; Rare disease; Research; Training

Indexed keywords

ARTICLE; CONTINUING EDUCATION; CURRICULUM; DEGENERATIVE DISEASE; DRUG INDUSTRY; EDUCATION; GOVERNMENT; HUMAN; INBORN ERROR OF METABOLISM; INVESTMENT; KNOWLEDGE; MEDICAL SCHOOL; NEURONAL CEROID LIPOFUSCINOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RARE DISEASE; TEACHING; TEACHING HOSPITAL;

EID: 84940796249     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.06.018     Document Type: Article

References (38)

1. European Commission Rare diseases (n.d.), (accessed December 15, 2014). http://ec.europa.eu/health/ph_threats/non_com/rare_diseases_en.htm.
2. Office of Rare Diseases Research, National Institutes of Health Rare diseases and related terms (n.d.), (accessed December 15, 2014). http://rarediseases.info.nih.gov/RareDiseaseList.aspx.
3. NCL 2014. Abstracts of the 14th International Conference on Neuronal Ceroid Lipofuscinoses (Batten disease) & 2nd International Patients Organization Meeting. Medicina (B. Aires) 2014, 74 Suppl. II:11-33. R. Kohan, I.A. Cismondi, I. Noher de Halac (Eds.).
4. Stehr F., Forkel M. Funding resources for rare disease research. Biochim. Biophys. Acta 2013, 1832:1910-1912. 10.1016/j.bbadis.2013.04.016.
5. Stern G. Niemann-Pick's and Gaucher's diseases. Parkinsonism Relat. Disord. 2014, 20(Suppl. 1):S143-S146. 10.1016/S1353-8020(13)70034-8.
6. Alcalay R.N., Dinur T., Quinn T., Sakanaka K., Levy O., Waters C., et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014, 71:752-757. 10.1001/jamaneurol.2014.313.
7. Ruano-Ravina A., Pérez-Ríos M. Regarding a case report: rare diseases and bibliometric impact factor. J. Clin. Epidemiol. 2012, 65:916-917. 10.1016/j.jclinepi.2012.02.015.
8. Matías-Guiu J., García-Ramos R. The impact factor and editorial decisions. Neurologia 2008, 23:342-348.
9. Forrest C.B., Bartek R.J., Rubinstein Y., Groft S.C. The case for a global rare-diseases registry. Lancet 2011, 377:1057-1059. 10.1016/S0140-6736(10)60680-0.
10. National Organization for Rare Disorders Significance of Rare Diseases (n.d.), (accessed December 15, 2014). http://www.rarediseaseawareness.com/legislation-support/significance-of-rare-diseases.
11. Ratko T.A., Marbella A., Godfrey S., Aronson N. Enzyme-Replacement Therapies for Lysosomal Storage Diseases 2013, Agency for Healthcare Research and Quality, US.
12. Eurodis The Voice of Rare Disease Patients in Europe (n.d.), (accessed December 15, 2014). http://www.eurordis.org/.
13. Kontoghiorghe C.N., Andreou N., Constantinou K., Kontoghiorghes G.J. World health dilemmas: orphan and rare diseases, orphan drugs and orphan patients. World J. Methodol. 2014, 4:163-188. 10.5662/wjm.v4.i3.163.
14. Kohan R., Cismondi I.A., Oller-Ramirez A.M., Guelbert N., Anzolini T.V., Alonso G., et al. Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr. Pharm. Biotechnol. 2011, 12:867-883.
15. Groft S.C. Rare diseases research: expanding collaborative translational research opportunities. Chest 2013, 144:16. 10.1378/chest.13-0606.
16. Department of Health, UK Government The UK Strategy for Rare Diseases 2013.
17. The National Organization for Rare Disorders (NORD) (n.d., accessed December 15, 2014). https://www.rarediseases.org/.
18. U.S.Food and Drud Administration Developing Products for Rare Diseases & Conditions (accessed January 12, 2015). http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ucm2005525.htm.
19. Office of Rare Diseases Research, National Institutes of Health (n.d., accessed January 12, 2015). http://rarediseases.info.nih.gov/.
20. United Nations Educational Scientific and Cultural Organization Universal Declaration on Bioethics and Human Rights (accessed January 04, 2015). http://www.unesco.org/new/es/.
21. United Nations Convention on the Rights of Persons with Disabilities and Optional Protocol 2008, 1-37. (http://www.un.org/disabilities/documents/convention/convoptprot-e.pdf).
22. Eggink H., Kuiper A., Peall K.J., Contarino M., Bosch A.M., Post B., et al. Rare inborn errors of metabolism with movement disorders: a case study to evaluate the impact upon quality of life and adaptive functioning. Orphanet J. Rare Dis. 2014, 9:177. 10.1186/s13023-014-0177-6.
23. Zeltner N.A., Huemer M., Baumgartner M.R., Landolt M.A. Quality of life, psychological adjustment, and adaptive functioning of patients with intoxication-type inborn errors of metabolism ¿ a systematic review. Orphanet J. Rare Dis. 2014, 9:159. 10.1186/s13023-014-0159-8.
24. Soon S.-S., Lopes G., Lim H.-Y., Wong-Rieger D., Bahri S., Hickinbotham L., et al. A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region. Orphanet J. Rare Dis. 2014, 9:137. 10.1186/s13023-014-0137-1.
25. The Human Variome Project (n.d., accessed January 06, 2015). http://www.humanvariomeproject.org/.
26. Sociedad Latinoamericana de Errores Innatos del Metabolismo y Pesquisa Neonatal (SLEIMPN) (n.d., accessed January 06, 2015). http://www.sleimpn.org/.
27. Ley 26.689 Cuidado integral de la salud de las personas con Enfermedades Poco Frecuentes (accessed April 16, 2015). http://infoleg.gob.ar/infolegInternet/anexos/185000-189999/185077/norma.htm.
28. 2014 Report on the State of the Art of Rare Disease Activities in Europe 2014, C. Rodwell, S. Aymé (Eds.).
29. de Melo-Martín I., Sondhi D., Crystal R.G. When ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trials. Hum. Gene Ther. 2011, 22:1121-1127. 10.1089/hum.2010.230.
30. Kleiderman E., Knoppers B.M., Fernandez C.V., Boycott K.M., Ouellette G., Wong-Rieger D., et al. Returning incidental findings from genetic research to children: views of parents of children affected by rare diseases. J. Med. Ethics 2014, 40:691-696. 10.1136/medethics-2013-101648.
31. Ross L.F., Ross L.F., Saal H.M., David K.L., Anderson R.R. Technical report: ethical and policy issues in genetic testing and screening of children. Genet. Med. 2013, 15:234-245. 10.1038/gim.2012.176.
32. Augustine E.F., Adams H.R., Beck C.A., Vierhile A., Kwon J., Rothberg P.G., et al. Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis. Dev. Med. Child Neurol. 2014, 10.1111/dmcn.12634.
33. Schulz A., Kohlschütter A. NCL disorders: frequent causes of childhood dementia., Iran. J. Child Neurol. 2013, 7:1-8.
34. Nourissier C. Medical education: the role of patients. Orphanet J. Rare Dis. 2010, 5:O26. 10.1186/1750-1172-5-S1-O26.
35. Bellagambi S. The Italian project to increase health professionals' training and awareness on rare diseases. Orphanet J. Rare Dis. 2012, 7:A16. 10.1186/1750-1172-7-S2-A16.
36. Vadachkoriia Z.O., Abesadze G.G., Pagava K.I., Korinteli I.A. University center on rare diseases, as a successful example of the integration of the clinical sector into the system of medical education. Georgian Med. News 2011, 20-22.
37. von Gizycki R. Contribution of rare disease patient organisations to medical education. Orphanet J. Rare Dis. 2010, 5:O25. 10.1186/1750-1172-5-S1-O25.
38. Collins F.S., Varmus H. A new initiative on precision medicine. N. Engl. J. Med. 2015, 372:793-795. 10.1056/NEJMp1500523.